No, they don't. First of all, let's be clear. Based on objective studies, only about one in 10 new drugs that are introduced in any given year make a substantial difference to the therapy that people get. Over half of the drugs that are introduced are actually what are sometimes called me-too drugs. In other words, they're an attempt to get into the market, but they don't offer any additional value.
As far as how quickly countries access the drugs, that largely depends on the size of the market. Canada, as the representative from Janssen said, is 2% of the worldwide market. The United States is about 40%. Some European countries are 10%. Companies are going to go to those markets first because they start to get money back earlier on. Canada is later on. In fact, companies wait about six months longer to file for approval in Canada compared to the United States.